Clinicopathological Characteristics of Salivary Gland Mucoepidermoid Carcinoma In dr Hasan Sadikin Central Hospital (RSHS) Bandung
A 10 Year review
DOI:
https://doi.org/10.55816/mpi.v33i2.596Abstract
Background
Primary salivary gland malignancy is rare and has limited reports. Mucoepidermoid Carcinoma (MEC) is the most common malignant tumor of the salivary glands. However, epidemiological reports on salivary gland MEC are still limited, particularly in Indonesia. This study aimed to report the clinicopathological characteristics of Salivary gland MEC in dr Hasan Sadikin Central Hospital (RSHS) from January 2013 to December 2022.
Method:
This study is a descriptive study with a cross-sectional method. Total cases of salivary glands MEC that were histopathologically diagnosed and recorded in the RSHS Hospital Information System (SIRS) medical records from 2013 to 2022 were collected. It is included demographic, clinical, and histopathological data.
Result
A total of 86 MEC cases were diagnosed histopathologically between 2013 and 2022. The cases involved 44 (51,2%) females and 42 (48,8%) males. The mean age is 46,4 years old. The most common site affected is a parotid gland (37,2%). According histopathological grade, 51,2% were high grade, 25,6% were intermediate grade, and 23,3% were low grade. The result of clinical stage is Stage III has the highest percentage (n=32, 37,2%). The majority of patients receive surgical combined with radiotherapy treatment (n=53; 61,6%).
Conclusion
There are 86 cases of Salivary MEC in RSHS period 2013-2022. MEC is common in females, mean age 46,4 years old. Parotid gland is the most common site. The most frequent histopathological grading and clinical staging are high grade and stage III.
Keyword
Mucoepidermoid carcinoma, salivary gland, clinicopathological, RSHS
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Maya Noor Fitriana, Hermin Aminah Usman, Anglita Yantisetiasti
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.